How DankeSuper plotted this
The hedge against CBN's evidence gap.
The CBN sleep claim is the cannabis industry's most-marketed, least-evidenced
assertion. Pillow Talk's design is interesting because it hedges against
that gap by adding melatonin — a cannabinoid pairing backstopped by
an actually-evidenced botanical.
Cannabinoid step
Δ9-THC10 mg× 1.0=10.0 alt
CBN5 mg× 0.13=0.65 alt
Subtotal10.65 mg Δ9-eq → Airplane
Botanical modifier step
Melatonin 3 mg (clinical range, though low-dose 0.3–1 mg outperforms
high-dose for onset): vector (0.45, 0.05, 0.50, 0.00), intensity 0.15.
Final quadrant lean
Sustained dominates at 0.49 — CBN's quadrant pull plus melatonin's
circadian Sustained vector together produce a clean Decompress placement.
Final: Decompress / Airplane, MODERATE confidence.
Cannabinoid per Framework v1.
Melatonin scoring per Botanical Module v1
(Brzezinski 2005 dose-response review). Confidence reflects CBN's LIMITED
sedation evidence (Corroon 2021) but STRONG melatonin support.
Review
3 min read
By DankeSuper editorial
The honest sleep gummy.
Pillow Talk is the rare cannabis sleep product whose stack actually makes
sense on inspection. The 10mg THC provides the altitude. The 5mg CBN is the
industry's load-bearing sedation claim — but the framework treats CBN with
LIMITED confidence on sedation because the modern evidence is thin (Corroon
2021 systematic review found no rigorous human trials of isolated CBN for
sleep). The 3mg melatonin is what does the actual work documented in
clinical literature: signal "biological night" to the SCN, accelerate sleep
onset by ~30 minutes.
The architectural read: Ayrloom designed Pillow Talk by either (a) being aware
that CBN's sleep narrative is weakly supported and adding melatonin as the
real active, or (b) independently arriving at the dose that produces the effect
consumers report. Either way, the formulation is more defensible than the typical
"30mg CBN sleep gummy" — which Ayrloom also makes (Dreamweaver) and which we
handle separately as a pure-cannabinoid bet without the melatonin hedge.
Editorial note · the melatonin dose-response inversion
Clinical literature consistently shows that lower melatonin doses
(0.3–1 mg) outperform higher doses (3–10 mg) for sleep-onset
latency. Pillow Talk's 3mg is at the upper end of useful and the lower end
of over-clinical. Consumers using it nightly may want to split a gummy to
test the lower-dose response.